Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2032

Conditions
Breast Cancer
Interventions
RADIATION

Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.

Trial Locations (1)

Unknown

Tianjin medical university cancer institute and hospital, Tianjin

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

The First Affiliated Hospital of Hainan Medical University

OTHER_GOV

collaborator

Shandong Cancer Hospital and Institute

OTHER

collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

collaborator

Chongqing University Cancer Hospital

OTHER

collaborator

Tangshan People's Hospital

OTHER

collaborator

Taizhou Hospital

OTHER

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06498154 - Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy | Biotech Hunter | Biotech Hunter